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Mastoparan inhibited PH]inositol phosphate accumulation induced by carbachol as well as cyclic AMP accumulation induced by isoproterenol 
in 1321Nl human astrocytoma cells. Mastoparan inhibited GTPyS-induced, but not Caz+-induced, PH]ino sitol phosphate accumulation in 
membrane preparations with an K,, of approximately IO pM. The inhibitory effect of mastoparan on carbachol-induced fH]inositol phosphate 
a~umulation was resistant o pertussis toxin (IAP) reagent in intact cells. These results suggest hat mastoparan inhibits phospholipa~ C in 
human astrocytoma cells via a GTP binding protein, which is not a substrate for IAP. 
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1. INTRODUCTION 
Mastoparan is a wasp venom toxin with a structure 
of Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys- 
Lys-Be-Leu-NHz, which has several ph~macologic~ 
effects, such as secretion of hist~ine from mast cells, 
secretion of serotonin from platelets and secretion of 
catecholamines from chromaffin cells [ 1,2]. Histamine 
release from mast cells by mastoparan has been in- 
vestigated in detail. Mastoparan stimulates hydrolysis 
of phosphatidylinositol bisphosphate in mast cells [3], 
producing two second messengers, inositol trisphos- 
phate [4] and diacylglycerol [S]. The release of his- 
tamine by mastoparan was inhibited by IAP, indicating 
that a G-protein which is a substrate for IAP was in- 
volved in mastoparan-induced activation of histamine 
release [6]. Recently, Higashijima et al. [7] reported 
that mastoparan increased the binding of [35S]GTPyS 
to purified G, and/or Gi in phospholipid vesicles and 
also stimulated GTPase activities of G,. Increase in the 
[35S]GTPyS binding to G, by mastoparan was partially 
attenuated by IAP treatment. The data suggest that 
mastoparan might interact with an IAP-sensitive G- 
protein directly. 
membrane control. The cells have adrenergic @- 
receptors [8], Ai-adenosine receptors 191, muscarinic 
receptors [lo], Hi-histamine receptors [ll], bradykinin 
receptors [12] and thromboxane A2 receptors [13]. 
Phosphoinositide hydrolysis induced by stimulations of 
muscarinic, Ha-histamine, bradykinin and thrombox- 
ane A2 receptors is dependent on GTP, but resistant o 
IAP treatment [11,13-151, meaning that a G-protein 
involved in phospholipase C activation is not a sub- 
strate for IAP in human astrocytoma cells. 
In the present study, the effect of mastoparan on 
phosphoinositide hydrolysis was examined in human 
astrocytoma cells. The results suggest hat mastoparan 
potently inhibits phosphoinositide hydrolysis in these 
cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
Human astrocytoma cells (1321Nl) proved to be a 
useful cell line to investigate receptor-mediated trans- 
Fetal bovine serum was obtained from Cell Culture Laboratory 
(Cleveland, OH, USA). Aluminum oxide (neutral) was from Merck. 
Mastoparan was from Peptide Institute (Osaka, Japan). IAP was 
from Funakoshi Pharmaceutical (Tokyo, Japan). [2-‘H]Myo-inositol 
was purchased from American Radiola~led Chemicals (St. Louis, 
MO, USA). The sources of other reagents were those described in 
v31. 
2.2. Cell culture 
Correspondence address: N. Nakahata, Department of Phar- 
macology, Fukushima Medical College, Fukushima 960-12, Japan 
Abbreviations: IAP, islet activating protein @ertussis toxin); 
GTPyS, guanosine 5 ’ -[r-thioltriphosphate; G-protein, guanine 
nucleotide regulatory protein; cyclic AMP, adenosine 3 ’ ,5 ‘-mono- 
phosphate; DMEM, Dulbecco’s modified Eagle’s medium; EMEM, 
Eagle’s minimum essential medium 
Human astrocytoma cells (1321Nl) were grown on 150-mm culture 
dishes in DMEM containing 5% fetal bovine serum, 50 U/ml of 
penicillin and 50 fig/ml of stre~omycin. Cells were maintained in a 
37°C humidified incubator in an atmosphere of 95% air and 5% 
coz. 
2.3. Determination of cyclic AMP 
Cells were grown on 35 mm or 1%well plates at a density of 10’ 
cells/ml after subculture with trypsin. Cells were used 4 days after the 
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subculture. Incubation was started by addition of drugs in EMEM- 
Hepes (pH 7.35) after several washes of cells with EMEM-Hepes (pH 
7.35). The reaction was terminated by addition of 1 ml of 5% TCA 
after aspiration of the medium. The TCA-extracted materials were 
applied to a 1 ml column with a bed volume of aluminum oxide 
(neutral). Cyclic AMP was eluted by 3 ml of 0.5 M Tris-HCI (pH 7.4) 
after washing the column with 4 ml of water. Cyclic AMP was deter- 
mined by a binding-protein method, described previously [16]. 
2.4. Assay of [3H]inositol phosphates in intact cells 
Phosphoinositide breakdown was monitored by measuring [3H]in- 
ositol phosphates as previously described [11,13]. Cells were grown 
on 35-mm dishes or 12-well plates at a density of lo5 cells/ml after 
subculture. The monolayers were labeled with DMEM containing 
[‘Hlinositol (1 &i/ml). Incubation was started by the addition of 
drugs to EMEM-Hepes (PH 7.35) containing 10 mM LiCl, and was 
terminated by the addition of 1 ml of 5% TCA. After removing TCA 
by ether washes, total inositol phosphates were separated by an 
anion-exchange column (AC 1X-8). 
2.5. Assay of ~H]inositol phosphates in membrane preparations 
The preparation of membranes and the analysis of [‘Hlinositol 
phosphates in the membrane preparations were done with essentially 
the same method as previously described [13,17]. Membranes 
(SO-100/g) containing [‘Hlphosphoinositides (30000-85000 dpm) 
were used for one assay. 
2.6. Data analysis 
The statistical significance of the difference between the values ob- 
tained was determined with the paired Student’s t-test. 
3. RESULTS 
Isoproterenol (10 PM)-activated adenylate cyclase, 
resulted in an accumulation of cyclic AMP in 1321Nl 
human astrocytoma cells (fig. 1). Mastoparan (30 PM) 
inhibited the accumulation of cyclic AMP induced by 
isoproterenol, supporting the observation that masto- 
paran could directly activate Gi/G, reported by Higas- 
hijima et al. [7]. In addition to inhibition of cyclic 
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Fig.1. Effect of mastoparan on cyclic AMP accumulation and 
inositol phosphate accumulation. (a) Mastoparan (30 pM, MP) 
significantly inhibited isoproterenol (10 pM, lSO)-induced cyclic 
AMP accumulation (* P < 0.05). (b) MP (30 PM) significantly 
inhibited carbachol (100 CM, CARB)-induced inositol phosphate 
accumulation (* P < 0.05). C, without drug. Results were mean * SE 
of three determinations. 
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Fig.2. Dose-response curve for GTPyS-induced accumulation of 
inositol phosphates in the presence (W---O) or absence (C---O) of 
30 ,uM mastoparan (MP) in membrane preparations. Membranes 
containing [‘Hlphosphoinositides (31000 dpm) were used for one 
assay. Results were mean + SE of three determinations. 
AMP accumulation, mastoparan (30pM) also in- 
hibited phosphoinositide hydrolysis induced by car- 
bachol(lO0 FM) in intact cells. Since there is no report 
that an activation of Gi inhibits phosphoinositide 
hydrolysis, the mechanism of inhibition of phospho- 
inositide hydrolysis by mastoparan might be different 
from an activation of Gi. 
To elucidate the inhibitory mechanism of masto- 
paran, we used membrane preparations in which G- 
proteins were directly activated. GTPyS (0.1-30 PM) 
increased inositol phosphate accumulation in a 
concentration-dependent manner (fig.2). GTPyS- 
induced inositol phosphate accumulation was potently 
inhibited by 30 PM mastoparan (fig.2). The inhibitory 
effect of mastoparan on GTPyS (10 PM)-induced ino- 
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Fig.3. Effect of mastoparan on GTPyS-induced inositol phosphate 
accumulation in membrane preparations. Mastoparan inhibited 
GTPyS (10 ,uM)-induced inositol phosphate accumulation (m), 
but did not affect the basal inositol phosphates (ti). Membranes 
containing [“Hlphosphoinositides (8 1000 dpm) were used for one 
assay. Results were mean + SE of three determinations. 
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Fig.4, Effect of mastoparan (MP) on GTP+- and Ca2+-induced 
accumulations of inositol phosphates in membrane preparations. MP 
significantly inhibited GTPyS (10 pM)-induced inositol phosphate 
accumulation (* P c 0.05), but not Ca2+ (1 mM)-induced accumula- 
tion. C, without drug. Membranes containing [‘Hlphosphoinositides 
(83000 dpm) were used for one assay. Results were mean + SE of 
three determinations. 
sitol phosphate accumulation was also dependent on 
the concentrations used (fig.3). Ca2+ ions are known to 
activate phospholipase C directly in millimolar concen- 
trations [ 15 3 _ M~toparan (30 PM) inhibited GTPyS 
(IO PM)-induced inositol phosphate accumulation, but 
not Ca’+ (1 mM)-induced accumulation (fig.4), in- 
dicating that mastoparan directly inhibited the activa- 
tion of the G-protein. 
Pretreatment of astroc~oma cells with IAP (100 
ng/mI) for 48 h elicited ADP-ribosylation of en- 
dogenous Gi [l 1,131, resulting in the inhibition of the 
receptor-Gi/G,-mediated response 191. However, the 
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Fig.% Effect of IAP on mastoparan (MP) inhibition of carbachol 
(CARB)-induced accumulation of inositol phosphates. The cells were 
treated with or without 100 ng/ml of IAP for 48 h. MP significantly 
inhibited CARB-induced inositoi phosphate accumulation (* P < 
0.05) with or without IAP treatment. C, without drug. Results were 
mean of: SE of three determinations, 
inhibitory effect of mastoparan on inositol phosphate 
accumulation induced by carbachol was resistant to 
treatment of the cells with IAP (fig.5), indicating that 
mastoparan inhibited a putative G-protein which ac- 
tivates phospholipase C and is insensitive to IAP. 
4. DISCUSSION 
The present study demonstrates that mastoparan in- 
hibits phosphoinositide hydrolysis in intact astro- 
cytoma cells as well as in the membrane preparations 
derived from these cells. Since mastoparan potently in- 
hibited GTPyS-induced phosphoinositide hydrolysis, 
but not Ca*+-induced hydrolysis in membrane prepara- 
tions, mastoparan might inhibit a putative G-protein to 
stimulate phospholipase C. Recently, Wojcikiewica 
and Nahorski [18] demonstrated that mastoparan in- 
hibited phosphoinositide hydrolysis induced by GTPyS 
in permeabilized SH-SYSY human neuroblastoma 
cells. They proposed a possibility that mastoparan in- 
teracts with polyphosphoinositides to inhibit their 
hydrolysis. In fact, mastoparan potently interacts with 
phospholipids [19]. However, mastoparan stimulates 
phosphoinositide hydrolysis in mast cells, possibly by 
activating an IAP-sensitive G-protein [6]. The interac- 
tion of mastoparan with polyphosphoinositides alone 
could not explain the mastoparan-induced hydrolysis 
of polyphosphoinositides in mast cells. Moreover, the 
fact that the inhibitory effect of mastoparan on 
Ca’+-induced phosphoinositide hydrolysis was not 
observed in human astrocytoma cells, and was extreme- 
ly weaker in SH-SYJY cells [18], indicates that masto- 
paran could inhibit a putative G-protein resulting in the 
inhibition of phosphoinositide hydrolysis. 
There are at least two G-proteins to activate phos- 
pholipase C, IAP-sensitive [20,21] and IAP-insensitive 
[ 11,13-151. It is interesting that mastoparan activates 
an IAP-sensitive G-protein to activate phospholipase C 
in mast celIs and it inhibits an IAP-insensitive one 
in astrocytoma cells. Discrimination of phospholipase 
C activation by mastoparan in different cell types sug- 
gests that there are at least two mechanisms of the G- 
protein-mediated activation of phospholipase C. 
In conclusion, mastoparan inhibits the G-protein 
which couples to phospholipase C in human astro- 
cytoma cells, and mastoparan could be an important 
toxin to analyze the mechanism of G-protein-mediated 
activations of phospholipase C. 
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